Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Journal of Gynecology Obstetrics and Human Reproduction|April 4, 2025
Identifying risk factors for postoperative complications following staging surgery for endometrial cancerShai Ram, Michael Lavie, Anna Assouline, et al.
Acta Obstetricia Et Gynecologica Scandinavica|October 13, 2020
Carboplatin plus paclitaxel weekly dose-dense chemotherapy for high-grade ovarian cancer: A re-evaluationRoy Kessous, Emad Matanes, Ido Laskov, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 3, 2025
Tailoring treatment for advanced and/or recurrent ovarian cancer using the response of circulating tumor cells to therapy: a retrospective analysisLyri Adar, Eliya Shachar, Ido Laskov, et al.
BMC Cancer|October 30, 2015
Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitorsOreekha Amin, Marie-Claude Beauchamp, Paul Abou Nader, et al.
Cancer Medicine|December 22, 2019
Biguanides in combination with olaparib limits tumorigenesis of drug-resistant ovarian cancer cells through inhibition of SnailQiong Wang, Vanessa M López-Ozuna, Tahira Baloch, et al.
The Oncologist|August 4, 2025
Survivorship in Advanced Ovarian Cancer: A Prognostic Model for Overall Survival and Risk of RecurrenceEliya Shachar, Yael Raz, Gilat Rotkop, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|September 29, 2018
Risk of Thromboembolic Disease With Cost Estimates in Patients Undergoing Robotic Assisted Surgery for Endometrial Cancer and Review of the LiteratureIdo Laskov, Roy Kessous, Jeremie Abitbol, et al.
Acta Obstetricia Et Gynecologica Scandinavica|January 19, 2020
CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancerRoy Kessous, Michel D Wissing, Sabrina Piedimonte, et al.
The Oncologist|July 14, 2020
Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian CancerTamar Safra, Barliz Waissengrin, Talya Levy, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Medical cannabis and its effect on oncological outcomes in patients with ovarian cancer treated with PARP inhibitorsShira Peleg Hasson, Eliya Shachar, Miriam R Brezis, et al.
Pageof 7